
    
      Eligible patients will be enrolled to the treatment arm based on breast cancer subtype.

      Patients will receive study treatment on Day 1 of a Q3W cycle. Treatment with CX-2009
      monotherapy (Arms A and B) or CX-2009 in combination with CX-072 (Arm C) will be given until
      disease progression or symptomatic deterioration, unacceptable toxicity necessitating
      treatment discontinuation, or if the patient meets certain study defined criteria for
      discontinuation. On-treatment tumor assessments, will occur every 6 weeks per RECIST v1.1 for
      the first 48 weeks, and every 12 weeks thereafter.
    
  